Vasopressin Market, by Type (Intravenous Injection, Intramuscular Injection, and Subcutaneous Injection), by Application, (Anti-Diuretic Hormone Deficiency, Gastrointestinal Bleeding, Vasodilatory Shock and Ventricular Tachycardia & Fibrillation), by End User (Hospitals, Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028
Vasopressin is antidiuretic hormone. It is naturally secreted by the pituitary gland, which acts on the kidneys and blood vessels. Vasopressin is used in the treatment of diabetes insipidus and certain conditions of the stomach after surgery or during abdominal x-rays. It is administered into a muscle or under the skin, or into a vein.
The global vasopressin market is estimated to be valued at US$ 1,112.6 million in 2021 and is expected to exhibit a CAGR of 14.7% over the forecast period (2021-2028).
Figure 1. Global Vasopressin Market Share (%) in Terms of Value, By Region, 2021
Increasing prevalence of autonomic dysreflexia (AD) is expected to drive growth of the global vasopressin market.
According to the National Center for Biotechnology Information (NCBI) 2017, the prevalence of AD in patients with spinal cord injury (SCI) has been reported to range from 20 to 70%, and it is known to occur in over 90% of patients with cervical or upper thoracic SCI.
Par Pharmaceutical, Pfizer Inc., Novartis AG, Ferring Pharmaceuticals, Fresenius Kabi Canada, Astellas Pharma, Shanghai Soho-Yiming Pharmaceuticals, Endo International, Hybio Pharmaceutical, Hainan Zhonghe Pharmaceutical, and Cumberland Pharmaceuticals
Figure 2. Global Vasopressin Market Share (%), by Type, 2021
The increasing regulatory approvals for vasopressin drug is expected to drive the market growth over the forecast period. For instance, in June 2021, Eagle Pharmaceuticals, Inc., announced that the U.S. Food and Drug and Administration priority review for the company’s abbreviated new drug application for its vasopressin.
The Eagle Pharmaceuticals, Inc., company’s response to the Complete Response Letter (CRL) was submitted on June 15, 2021. The U.S. FDA assigned a Generic Drug User Fee Amendments/Act GDUFA date of December 15, 2021
Global Vasopressin Market– Impact of Coronavirus (COVID-19) Pandemic-
The recent increasing cases of people suffering from Novel corona virus is expected to sudden increase of cardiac syndrome risk amongst people . This is leading the pharma sector to focus on research and development on advanced vasopressin drugs for treatment purposes. This is expected to boost the growth of the global market in the near future.
Global Vasopressin Market- Restraint
The major factor that is expected to hinder growth of the global vasopressin market include complication resulting from the use vasopressin such as asthma, epilepsy, heart disease, and heart failure.
Key Players
Major players operating in the global vasopressin market include Par Pharmaceutical, Pfizer Inc., Novartis AG, Ferring Pharmaceuticals, Fresenius Kabi Canada, Astellas Pharma, Shanghai Soho-Yiming Pharmaceuticals, Endo International, Hybio Pharmaceutical, Hainan Zhonghe Pharmaceutical, and Cumberland Pharmaceuticals.
Vasopressin is a nonapeptide produced in the hypothalamus, exhibits diverse physiological functions related to hemodynamic modulation, diuresis, and behavior. Vasopressin is similar to oxytocin, differing in the third and eight amino acid.
Vasopressin is indicated for the treatment of postoperative abdominal distention, abdominal roentgenography, Gastrointestinal Bleeding and diabetes insipidus.
Market Dynamics
The increasing approvals of vasopressin drug by regulatory authorities is expected to drive the global vasopressin market growth. For instance, in 2018, Eagle Pharmaceuticals, Inc., received abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration for its vasopressin injection, 1ml. Vasostrict had around US$ 400 million in brand sales in 2017, according to the Eagle Pharmaceuticals, Inc., company financial review.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
The global vasopressin market is estimated to be valued at US$ 1,112.6 million in 2021 and is expected to exhibit a CAGR of 14.7% between 2021 and 2028.
Increasing prevalence of autonomic dysreflexia (AD) and approvals of vasopressin drug are expected to drive the market growth over the forecast period.
Hospital segment is expected to hold major market share during the forecast period.
North America is expected to hold largest market share in the market.
Major players operating in the market include Par Pharmaceutical, Pfizer Inc., Novartis AG, Ferring Pharmaceuticals, Fresenius Kabi Canada, Astellas Pharma, Shanghai Soho-Yiming Pharmaceuticals, Endo International, Hybio Pharmaceutical, Hainan Zhonghe Pharmaceutical, and Cumberland Pharmaceuticals.
The global vasopressin market is estimated to be valued at US$ 1,112.6 million in 2021 and is expected to exhibit a CAGR of 14.7% between 2021 and 2028.
Increasing prevalence of autonomic dysreflexia (AD) and approvals of vasopressin drug are expected to drive the market growth over the forecast period.
Hospital segment is expected to hold major market share during the forecast period.
North America is expected to hold largest market share in the market.
Major players operating in the market include Par Pharmaceutical, Pfizer Inc., Novartis AG, Ferring Pharmaceuticals, Fresenius Kabi Canada, Astellas Pharma, Shanghai Soho-Yiming Pharmaceuticals, Endo International, Hybio Pharmaceutical, Hainan Zhonghe Pharmaceutical, and Cumberland Pharmaceuticals.
Liver disease is either inherited (genetic) or is caused b...
Allergy immunotherapy is the only casual treatment to prev...
Neuropathic pain is caused by a lesion or disease of the s...
Meningococcal disease is caused by the bacterium Neisseria...
Drug abuse testing has been established to be a clinical s...
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Kindly subscribe for our latest news & articles.
